Flupentixol: A Comprehensive Monograph on its Pharmacology, Clinical Use, and Safety Profile

1.0 Executive Summary

Flupentixol is a first-generation, or typical, antipsychotic agent belonging to the thioxanthene chemical class.[1] First introduced in 1965, it occupies a distinct niche in psychopharmacology due to its dose-dependent dual functionality, serving as a maintenance treatment for schizophrenia at higher doses and as a rapid-acting antidepressant at lower doses.[1] Its primary mechanism of action involves potent, non-selective antagonism of central dopamine D1 and D2 receptors, which is the basis for its antipsychotic efficacy.[3] The drug also exhibits antagonist activity at various other neuroreceptors, including serotonin 5-HT2A, alpha-1 adrenergic, and muscarinic M1 receptors, contributing to its complex profile of therapeutic and adverse effects.[3]

Clinically, Flupentixol is most prominently used for the long-term maintenance therapy of chronic schizophrenia, specifically in patients whose primary symptoms do not include excitement, agitation, or hyperactivity.[3] Its utility in this population is significantly enhanced by the availability of a long-acting intramuscular depot formulation, flupentixol decanoate. This formulation, administered every two to four weeks, addresses the critical challenge of medication non-adherence, a common cause of relapse in this patient population.[1]

The safety profile of Flupentixol is characteristic of a typical antipsychotic and is dominated by a high propensity for dose-dependent neurological adverse effects. These include acute extrapyramidal symptoms (EPS) such as parkinsonism, akathisia, and dystonia, as well as the risk of tardive dyskinesia (TD), a potentially irreversible movement disorder, with long-term use.[1] Other significant risks include hyperprolactinemia and cardiovascular effects, notably QTc interval prolongation.[1]

Flupentixol has a unique and divergent global regulatory status. It is approved and widely used in Canada, the United Kingdom, Australia, and various other countries across Europe and Asia.[1] However, it has never been approved for marketing in the United States, a decision that likely reflects differing regulatory assessments of its risk-benefit profile compared to newer, second-generation antipsychotics with a lower burden of neurological side effects.[1] This monograph provides a comprehensive examination of Flupentixol's chemical properties, pharmacology, clinical applications, and safety considerations.

2.0 Chemical Identity and Physicochemical Properties

2.1 Nomenclature and Identifiers

Flupentixol is the International Nonproprietary Name (INN) for the compound.[1] It has also been known by its former British Approved Name (BAN), flupenthixol.[1] The molecule is identified across various chemical and pharmacological databases by a range of synonyms and unique codes, ensuring its unambiguous identification in research and clinical contexts. Common synonyms include Flupenthixole, Flupentixolo, and Flupentixolum.[3]

Key identifiers for Flupentixol are consolidated in the table below:

Identifier Type	Value	Source(s)
DrugBank ID	DB00875	1
CAS Number	2709-56-0	1
PubChem CID	5281881	1
ChEMBL ID	CHEMBL42055	1
ATC Code	N05AF01	1
UNII (cis-isomer)	FA0UYH6QUO	7
KEGG ID	D01044, C11191	1

2.2 Molecular Structure and Stereochemistry

Flupentixol is a derivative of the thioxanthene tricyclic ring system.[1] Its chemical structure is characterized by a propyl-piperazine-ethanol side chain attached to the thioxanthene nucleus via a double bond, and a trifluoromethyl group on the thioxanthene ring.[5] The IUPAC name for the active isomer is 2-[(3Z)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol.[7]

A critical aspect of Flupentixol's chemistry is its geometric isomerism. Due to the exocyclic double bond, the molecule exists as two distinct geometric isomers: the cis(Z) isomer and the trans(E) isomer.[3] This stereochemistry is of paramount clinical importance, as pharmacological activity resides almost exclusively in the

cis(Z)-flupentixol isomer.[3] The

trans(E) isomer is considered pharmacologically inactive.[5] Consequently, the therapeutic efficacy of any Flupentixol formulation is entirely dependent on the presence and purity of the

cis(Z) isomer. This stereoselectivity mandates that manufacturing processes either be stereospecific or include rigorous purification steps to isolate the active isomer. For regulatory purposes, any generic formulation must demonstrate not only chemical identity but also the correct isomeric ratio to be considered therapeutically equivalent to the reference product.

For long-acting parenteral administration, the active cis(Z)-flupentixol is chemically modified by esterification with decanoic acid. This reaction forms flupentixol decanoate, a highly lipophilic ester prodrug.[3] This chemical modification is the basis for its formulation as a depot injection, as the ester must be hydrolyzed in vivo to release the active flupentixol moiety, thereby providing a slow, sustained therapeutic effect.[3]

2.3 Physical and Chemical Properties

The physical and chemical properties of Flupentixol vary significantly depending on its chemical form—the free base, the hydrochloride salt, or the decanoate ester. These differences directly influence the formulation and route of administration. The hydrochloride salt is used for oral tablets due to its water solubility, while the highly lipophilic decanoate ester is dissolved in a vegetable oil vehicle for intramuscular depot injection.[14] A comparison of these properties is presented in Table 2.1.

Table 2.1: Physicochemical Properties of Flupentixol and its Derivatives

Property	Flupentixol (Base)	Flupentixol Dihydrochloride	Flupentixol Decanoate
Chemical Formula	C23​H25​F3​N2​OS	C23​H25​F3​N2​OS⋅2HCl	C33​H43​F3​N2​O2​S
Average Molecular Weight	434.52 g/mol	507.4 g/mol	588.77 g/mol
Monoisotopic Mass	434.163969096 Da	Not specified	588.299734296 Da
Appearance	Not specified	White or yellowish-white powder	Yellow, viscous oil
Solubility (Water)	Very slightly soluble	Soluble	0.000107 mg/mL (practically insoluble)
Solubility (Organic)	Freely soluble in chloroform and ether, soluble in ethanol	Soluble in ethanol, very slightly soluble in chloroform, virtually insoluble in ether	Freely soluble in chloroform and ether, soluble in ethanol
logP	4.51	Not specified	7.21 - 8.75
Melting Point	233-234 °C (cis(Z)-isomer)	Not specified	Not applicable (oil)

Data compiled from sources:.[3]

3.0 Clinical Pharmacology

3.1 Mechanism of Action

Flupentixol's therapeutic effects are derived from its interactions with multiple central nervous system (CNS) neurotransmitter systems. It is a typical antipsychotic, and its primary mechanism of action is potent, non-selective antagonism of postsynaptic dopamine receptors.[16] It demonstrates high affinity as an antagonist for both dopamine D1 and D2 receptor subtypes, with studies indicating roughly equal affinity for both.[3] This broad-spectrum dopamine blockade, particularly in the brain's mesolimbic and mesocortical pathways, is believed to be the principal mechanism underlying its antipsychotic effects, reducing the positive symptoms of schizophrenia such as hallucinations and delusions.[2] The drug also binds with lower affinity to dopamine D3 and D4 receptors.[3]

Beyond the dopaminergic system, Flupentixol has a wide receptor binding profile, acting as an antagonist at several other key receptors [3]:

• Serotonin Receptors: It is an antagonist at 5-hydroxytryptamine (serotonin) receptor 2A (5−HT2A​) and 2C (5−HT2C​).[3] Antagonism at 5−HT2A​ receptors is thought to contribute to its anxiolytic properties and may modulate its antipsychotic effects.[3]
• Adrenergic Receptors: It is an antagonist at alpha-1A adrenergic receptors (α1A​).[3] This action is responsible for some of its side effects, including orthostatic hypotension and mild sedation.[3]
• Muscarinic Receptors: It possesses weak antagonist activity at muscarinic acetylcholine M1 receptors.[3] This accounts for its relatively mild anticholinergic side effect profile compared to some other typical antipsychotics.[3]

A particularly interesting aspect of Flupentixol's pharmacology is the proposed mechanism for its antidepressant effects at low doses. While the antipsychotic action is attributed to broad D2 receptor blockade, the antidepressant effect is not fully understood. A leading hypothesis suggests that at low concentrations, Flupentixol may exhibit functional selectivity or preferentially bind to and block presynaptic D2 autoreceptors.[1] These autoreceptors normally provide negative feedback to inhibit dopamine release. By blocking them, Flupentixol would disinhibit dopamine neurons, leading to increased synthesis and release of dopamine into the synapse. This net increase in postsynaptic dopaminergic activation could mediate its mood-elevating and activating properties, a mechanism distinct from its high-dose antipsychotic action.[1]

3.2 Pharmacodynamics

The multifaceted receptor binding profile of Flupentixol translates into a complex array of clinical pharmacodynamic effects, encompassing both therapeutic actions and adverse events. The relationship between receptor antagonism and clinical effect is summarized in Table 3.1.

Table 3.1: Receptor Binding Profile and Associated Pharmacodynamic Effects

Receptor Target	Action	Associated Therapeutic Effect(s)	Associated Adverse Effect(s)
Dopamine D1 & D2	Antagonist	Antipsychotic (alleviates positive symptoms), Antiemetic	Extrapyramidal Symptoms (EPS), Tardive Dyskinesia (TD), Hyperprolactinemia, Akathisia
Serotonin 5-HT2A	Antagonist	Anxiolytic, Potential modulation of antipsychotic effects and EPS	Weight gain
Alpha-1 Adrenergic	Antagonist	Mild Sedation	Orthostatic hypotension, Dizziness
Muscarinic M1	Antagonist	(Weak)	Dry mouth, Blurred vision, Constipation (effects are generally weak)

Data compiled from sources:.[2]

The primary pharmacodynamic effect at antipsychotic doses is the reduction of psychosis, stemming from D2 receptor blockade in the mesolimbic pathway.[3] However, this same mechanism in other dopamine pathways is responsible for its most significant liabilities. D2 blockade in the nigrostriatal pathway leads to EPS. D2 blockade in the tuberoinfundibular pathway disrupts the normal tonic inhibition of prolactin secretion, leading to hyperprolactinemia and its associated endocrine consequences.[1] The drug's antiemetic properties also arise from D2 antagonism, but in the chemoreceptor trigger zone of the brainstem.[3] Its anxiolytic and mild sedative actions are attributed to its effects on serotonin and adrenergic receptors, respectively.[3]

3.3 Pharmacokinetics

The pharmacokinetic profile of Flupentixol is critically dependent on its formulation and route of administration, with profound differences between the oral dihydrochloride salt and the intramuscular decanoate ester depot injection.[2]

3.3.1 Absorption

Following oral administration, Flupentixol is readily absorbed from the gastrointestinal tract but is subject to significant first-pass metabolism, resulting in a relatively low oral bioavailability of approximately 40%.[3] Maximum plasma concentrations (

Tmax​) are typically reached within 3 to 8 hours.[3]

In contrast, the flupentixol decanoate depot injection is designed for slow and sustained absorption. After intramuscular injection into a muscle mass like the gluteus maximus, the esterified drug slowly diffuses from the oily vehicle into the surrounding tissue fluid, where it is gradually hydrolyzed by esterases to release the active flupentixol moiety into the circulation.[3] This process results in a significantly delayed peak plasma concentration, with

Tmax​ occurring between 4 and 7 days after injection.[3] The drug is detectable in the blood for up to three weeks post-injection.[2]

3.3.2 Distribution

Flupentixol is widely distributed throughout the body, with an apparent volume of distribution (Vd​) of approximately 14.1 L/kg, indicating extensive tissue uptake.[3] It is highly lipophilic and demonstrates a very high degree of plasma protein binding, at approximately 99%.[3] Following administration, the highest concentrations of the drug are found in well-perfused organs such as the lungs, liver, and spleen, with lower concentrations found in the blood and brain.[3]

3.3.3 Metabolism

Flupentixol undergoes extensive hepatic metabolism to form pharmacologically inactive metabolites.[3] The primary metabolic pathways include sulfoxidation of the thioxanthene ring, N-dealkylation of the piperazine side chain, and conjugation with glucuronic acid.[3] As noted, the flupentixol decanoate prodrug is first hydrolyzed to active flupentixol before undergoing these metabolic transformations.[3]

3.3.4 Excretion

Elimination of Flupentixol and its metabolites occurs through both renal and fecal routes, with fecal excretion being the predominant pathway.[3] Unchanged Flupentixol and its lipophilic metabolites (e.g., dealkyl-flupentixol) are primarily recovered in the feces, while more hydrophilic metabolites, such as the sulfoxide and glucuronide conjugates, are excreted in the urine.[3]

The elimination half-life (t1/2​) differs dramatically between the two main formulations, a fact that underpins their distinct clinical applications. For the oral formulation, the elimination half-life is approximately 35 hours.[3] For the depot injection, due to the slow-release kinetics, the apparent elimination half-life is extended to approximately 3 weeks.[3] This prolonged half-life allows for the convenient bi-weekly or monthly dosing schedule but also presents a significant clinical challenge. In the event of severe adverse effects, the drug cannot be rapidly cleared from the body, and its pharmacological actions will persist for weeks. This reality necessitates careful patient selection, consideration of a test dose in vulnerable populations, and cautious dose titration.[14] Reaching steady-state plasma concentrations takes about 7 days with daily oral dosing but requires approximately 3 months of repeated administration with the depot injection.[3]

4.0 Therapeutic Indications and Clinical Efficacy

4.1 Schizophrenia and Other Psychoses

The primary and most well-established indication for Flupentixol is the maintenance therapy of chronic schizophrenia and related psychotic disorders.[2] Its use is specifically recommended for patients whose clinical presentation is not dominated by symptoms of excitement, agitation, or hyperactivity.[3] In this patient subset, often characterized by negative symptoms such as apathy and withdrawal, Flupentixol helps to prevent relapse of psychotic episodes.[4]

The cornerstone of its use in schizophrenia is the long-acting depot injection, flupentixol decanoate.[14] This formulation is particularly valuable for individuals with a history of poor compliance with oral medication, which is a major predictor of relapse.[1] By providing a sustained therapeutic level of the drug for two to four weeks with a single injection, it ensures treatment continuity and has been used for this purpose for over five decades.[1] The brand name Depixol® is commonly associated with its use in psychosis.[1]

4.2 Depressive Disorders

In addition to its antipsychotic properties, Flupentixol is indicated at low doses for the management of depression, which may or may not be accompanied by anxiety.[3] This dual functionality is unusual for a typical antipsychotic. The brand name Fluanxol® is specifically marketed for this indication.[1] Clinical evidence suggests that Flupentixol has a rapid onset of antidepressant action, with mood-elevating effects often observed within two to three days of initiating treatment, which can be an advantage compared to the delayed onset of many traditional antidepressants.[3]

4.3 Combination Therapy: Flupentixol/Melitracen

Flupentixol is also available in a fixed-dose combination product with melitracen, a tricyclic antidepressant.[1] This combination, marketed under brand names such as Deanxit and Placida, is indicated for the management of symptoms of anxiety, depression, and asthenia (a lack of energy).[3] The product leverages the potential synergistic effects of a low-dose antipsychotic with anxiolytic properties and a standard antidepressant.[26] However, this combination product is controversial and has a varied regulatory status globally. It has been banned in some countries and is not approved for marketing in several major markets, including the United States, the United Kingdom, Canada, and Australia.[25]

4.4 Investigational and Off-Label Applications

Beyond its approved indications, Flupentixol has been investigated for other psychiatric and medical conditions.

• Substance-Related Disorders: There is evidence of its investigation as a potential treatment to facilitate cocaine withdrawal. A completed Phase 2 clinical trial explored its use for treating cocaine abuse in patients with schizophrenia.[23]
• Deliberate Self-Harm: Tentative evidence suggests that low-dose Flupentixol may reduce the rate of deliberate self-harm in individuals who engage in this behavior repeatedly.[1] This effect may be linked to its antidepressant and anxiolytic properties, as well as potential effects on impulse control.
• Oncology: Recent preclinical research has uncovered potential anti-tumor properties. One study demonstrated that Flupentixol can dock to the ATP binding pocket of phosphatidylinositol 3-kinase (PI3K), inhibiting the PI3K/AKT signaling pathway, which is often hyperactivated in certain cancers. This led to reduced survival of lung cancer cells both in vitro and in vivo.[3] This remains an area for future investigation.

The use of long-acting injectable first-generation antipsychotics for conditions beyond schizophrenia is a recognized practice in psychiatry. Although direct evidence for Flupentixol is limited, broader studies show that depot antipsychotics are frequently used off-label for conditions such as bipolar disorder and personality disorders, particularly in patients with poor adherence and significant mood lability or hostility.[29] This suggests a clinical practice pattern where the reliable delivery system of depot formulations is leveraged to manage challenging symptoms in difficult-to-treat populations, even without formal approval for these indications.

5.0 Dosage and Administration

5.1 Formulations

Flupentixol is commercially available in two primary forms for administration:

• Oral Tablets: As flupentixol dihydrochloride, available in strengths of 0.5 mg, 1 mg, and 3 mg.[11] A 5 mg tablet is also available in some regions.[30]
• Depot Intramuscular Injection: As flupentixol decanoate in an oily solution. It is available in two concentrations:
• Fluanxol Depot / Depixol: 20 mg/mL.[11]
• Fluanxol Concentrated Depot / Depixol Conc.: 100 mg/mL, for patients requiring higher doses or smaller injection volumes.[14]

5.2 Dosing Regimens by Indication

The dosing of Flupentixol is highly specific to the indication and the formulation used. The significant difference in dosage between its antidepressant and antipsychotic uses necessitates careful prescribing and dispensing to avoid medication errors.

Table 5.1: Recommended Dosing Schedules for Flupentixol Formulations

Indication	Formulation	Starting Dose	Titration / Schedule	Maintenance Dose	Maximum Dose
Depression	Oral Tablets	Adults: 1 mg once daily (morning) Elderly (>65): 0.5 mg once daily (morning)	After 1 week, may increase to 2 mg/day (Adults) or 1 mg/day (Elderly).	Determined by clinical response.	Adults: 3 mg/day Elderly: 1.5 mg/day
Schizophrenia	Oral Tablets	1 mg three times daily.	Dose may be gradually increased.	3 mg to 6 mg daily in divided doses.	Not specified, but EPS risk increases >10 mg/day.3
Schizophrenia (Maintenance)	Depot Injection	Test Dose: 5 mg to 20 mg is recommended for neuroleptic-naïve or sensitive patients. Standard Start: 20 mg to 40 mg.	A second dose may be given 4-10 days after the first. Subsequent injections every 2-4 weeks.	20 mg to 40 mg every 2 to 4 weeks.	Doses >100 mg per fortnight are generally not necessary.18

Data compiled from sources:.[2]

For patients transitioning from oral antipsychotics to the depot injection, oral medication may be continued at a diminishing dose during the initial period until the depot injection reaches therapeutic levels.[18] When switching from another depot antipsychotic like fluphenazine decanoate, a dose conversion ratio is used (e.g., 25 mg fluphenazine decanoate is approximately equivalent to 40 mg flupentixol decanoate).[18] The injection must be administered deep intramuscularly into the gluteus maximus and must never be given intravenously.[14]

5.3 Special Populations

• Elderly Patients (> 65 years): Elderly patients should receive half the recommended adult dosage for depression due to potential for increased sensitivity and reduced clearance.[22] For schizophrenia, a lower test dose (e.g., 5 mg) of the depot injection is recommended for frail or elderly individuals.[14]
• Pediatric Patients (< 18 years): The safety and efficacy of Flupentixol have not been established in children and adolescents; therefore, its use is not recommended in this population.[30]
• Hepatic and Renal Impairment: Flupentixol is extensively metabolized by the liver. In patients with significant hepatic impairment, cautious dosing is required, and serum level monitoring may be advisable.[18] Caution is also advised in patients with renal insufficiency.[2]

6.0 Safety Profile and Risk Management

6.1 Adverse Drug Reactions

The adverse effect profile of Flupentixol is consistent with its classification as a typical, first-generation antipsychotic, with neurological side effects being particularly prominent.

6.1.1 Neurological Effects

• Extrapyramidal Symptoms (EPS): These are common, dose-dependent, and often appear soon after initiating therapy or increasing the dose.[1] EPS includes a range of movement disorders:
• Parkinsonism: Characterized by tremor, muscle rigidity, hypokinesia (slowness of movement), and a mask-like facial expression.[1]
• Akathisia: A state of inner restlessness and a compelling need to be in constant motion.[1]
• Acute Dystonia: Involuntary muscle spasms, which can affect the neck (torticollis), eyes (oculogyric crisis), or other body parts.[1]

These effects are manageable with dose reduction or the administration of antiparkinsonian medications.3

• Tardive Dyskinesia (TD): A serious, potentially irreversible movement disorder that can develop after long-term treatment.[1] It is characterized by repetitive, involuntary, purposeless movements, often involving the face, lips, tongue (lip-smacking, grimacing), and limbs.[1] The risk of TD is a major concern with all typical antipsychotics.
• Neuroleptic Malignant Syndrome (NMS): A rare but potentially fatal medical emergency that can occur at any time during treatment.[1] It is characterized by a clinical tetrad of hyperthermia, severe muscle rigidity ("lead-pipe" rigidity), autonomic instability (tachycardia, labile blood pressure, diaphoresis), and altered mental status (confusion, coma).[1] Immediate discontinuation of the drug and intensive supportive care are required.

6.1.2 Cardiovascular Effects

Flupentixol can affect cardiac electrical conduction, primarily by causing a prolongation of the QTc interval on an electrocardiogram (ECG).[1] A persistently prolonged QTc interval increases the risk of life-threatening cardiac arrhythmias, such as Torsades de Pointes.[1] This risk is heightened in susceptible individuals (e.g., those with hypokalemia, hypomagnesemia, or a genetic predisposition), in cases of overdose, or when co-administered with other QTc-prolonging drugs.[1] Other cardiovascular effects include orthostatic hypotension and tachycardia, primarily due to alpha-1 adrenergic blockade.[1]

6.1.3 Endocrine Effects

Dopamine D2 receptor blockade in the tuberoinfundibular pathway leads to increased prolactin secretion (hyperprolactinemia).[1] Clinically, this can manifest as:

• In Females: Amenorrhea (cessation of menstrual cycles), galactorrhea (inappropriate milk production), and potential infertility.[1]
• In Males: Gynecomastia (enlargement of breast tissue), sexual dysfunction, and decreased sperm production.[1]

Long-term hyperprolactinemia may be associated with decreased bone mineral density and an increased risk of osteoporosis.1

6.1.4 Other Common and Serious Effects

• Common Effects: Drowsiness, dizziness, dry mouth, constipation, blurred vision, increased salivation, and weight changes are frequently reported.[1]
• Serious Effects: Other less common but serious adverse effects include seizures (as it can lower the seizure threshold), blood dyscrasias, jaundice, abnormal liver function tests, and venous thromboembolism.[1]

6.2 Contraindications and Precautions

Flupentixol is subject to several absolute contraindications and numerous warnings.

Contraindications:

• Known hypersensitivity to Flupentixol, other thioxanthenes, or phenothiazines.[2]
• Depressed level of consciousness from any cause, including acute intoxication with alcohol, barbiturates, or opiates.[14]
• Circulatory collapse or coma.[14]
• Phaeochromocytoma (a rare adrenal gland tumor).[4]
• Blood dyscrasias.[14]

Precautions and Warnings:

• Elderly Patients with Dementia: Flupentixol is not indicated for the treatment of dementia-related psychosis. Like other antipsychotics, it is associated with an increased risk of cerebrovascular adverse events, stroke, and death in this population.[3]
• Cardiovascular Disease: Use with caution in patients with a history of cardiovascular disorders, known QT prolongation, significant bradycardia, or electrolyte imbalances.[14]
• Seizure Disorders: Use with caution in patients with a history of seizures or conditions that lower the seizure threshold, such as organic brain syndrome.[14]
• Parkinson's Disease: Flupentixol can worsen the motor symptoms of Parkinson's disease and should generally be avoided.[2]
• Glaucoma: Due to its weak anticholinergic effects, it should be used with caution in patients with narrow-angle glaucoma.[18]
• Hepatic/Renal Impairment: Use with caution due to reliance on hepatic metabolism and renal/fecal excretion.[14]

6.3 Management of Overdose

Overdose with Flupentixol can be life-threatening. Symptoms typically include an initial phase of agitation and confusion, followed by profound sedation, somnolence, coma, and possibly convulsions.[2] Severe cardiovascular toxicity (hypotension, QT prolongation, Torsades de Pointes, ventricular arrhythmias, cardiac arrest) and respiratory depression can occur.[2] Hyperthermia or hypothermia may also be present.[2]

Management is primarily symptomatic and supportive.[3] Key interventions include:

• Airway Management: Securing and maintaining a patent airway is the first priority.
• Gastric Decontamination: For oral overdose, gastric lavage may be considered if performed soon after ingestion.[3]
• Cardiovascular Support: Continuous ECG monitoring is essential. For severe hypotension, intravenous vasopressors should be used. Epinephrine must not be used, as Flupentixol's alpha-adrenergic blockade can lead to a paradoxical further drop in blood pressure (epinephrine reversal). Vasopressors like levarterenol (norepinephrine) are preferred.[3]
• Management of EPS: Antiparkinsonian medication should be administered if extrapyramidal symptoms develop.[3]
• Depot Overdose: In the case of an overdose from the depot injection, further injections should be withheld until the patient shows signs of relapse, at which point treatment can be cautiously restarted at a lower dose.[3]

7.0 Clinically Significant Drug Interactions

7.1 Pharmacodynamic Interactions

Flupentixol can interact with numerous other medications through additive or antagonistic pharmacodynamic effects.

• CNS Depressants: Concomitant use with other CNS depressants, including alcohol, benzodiazepines, opioids, and barbiturates, can lead to additive sedation and respiratory depression. Patients should be advised to avoid alcohol.[2]
• QTc-Prolonging Drugs: The risk of malignant arrhythmias is increased when Flupentixol is used with other medications known to prolong the QTc interval. This includes certain antiarrhythmics (e.g., quinidine), macrolide antibiotics, and some other psychotropic drugs like tricyclic antidepressants and 5-HT3 antagonists.[1]
• Antihypertensive Agents: Flupentixol can enhance the hypotensive effects of many antihypertensive drugs. It may also block the therapeutic effect of certain agents like guanethidine.[2]
• Anticholinergic Drugs: Additive anticholinergic effects can occur when combined with other drugs with antimuscarinic properties (e.g., atropine, some antidepressants), increasing the risk of side effects like constipation, urinary retention, and blurred vision.[18]

7.2 Target-Mediated Interactions

The broad receptor profile of Flupentixol creates a high potential for interactions at the receptor level.[34]

• Dopamine Receptors: As a dopamine antagonist, Flupentixol will directly oppose the effects of dopamine agonists used to treat Parkinson's disease (e.g., levodopa, apomorphine, bromocriptine) and may reduce their efficacy.[2]
• Alpha-1 Adrenergic Receptors: Co-administration with other alpha-1 antagonists can lead to additive hypotension. Conversely, its effects may be opposed by alpha-1 agonists.[34]
• Muscarinic M1 Receptors: Its weak anticholinergic effects can be potentiated by other M1 antagonists. It will oppose the action of M1 agonists like pilocarpine and cevimeline.[34]
• Serotonin 5-HT2A Receptors: The effects of 5-HT2A agonists (e.g., certain hallucinogens) may be blocked. Additive effects may occur with other 5-HT2A antagonists.[34]

8.0 Regulatory Status and Global Availability

8.1 Marketing Authorizations

Flupentixol was first introduced by the pharmaceutical company Lundbeck in 1965.[1] Its regulatory status shows a notable divergence across major global markets.

It is approved for use in numerous countries, including:

• Canada: Approved by Health Canada's Therapeutic Products Directorate.[1]
• Australia: Approved and listed on the Pharmaceutical Benefits Scheme (PBS) as a Schedule 4 (Prescription Only) medicine.[1]
• United Kingdom and Europe: Widely available in the UK as a Prescription Only Medicine (POM) and is nationally authorized in many European Union member states, including Germany, Ireland, Denmark, and Sweden.[4]

In stark contrast, Flupentixol is not, and has never been, approved for marketing in the United States by the U.S. Food and Drug Administration (FDA).[1] This lack of approval in one of the world's largest pharmaceutical markets is significant. This regulatory divergence likely stems from different assessments of the drug's risk-benefit profile. By the time Flupentixol might have been considered for the US market, second-generation (atypical) antipsychotics were emerging. These newer agents offered a similar or superior efficacy profile with a substantially lower risk of the severe neurological side effects, particularly tardive dyskinesia, that are characteristic of typical antipsychotics like Flupentixol. The FDA may have concluded that its safety profile was unfavorable given the availability of safer alternatives. Conversely, its continued use in health systems like the UK's NHS and in Canada and Australia suggests that these regulatory bodies still recognize a valuable clinical niche for Flupentixol, primarily for its long-acting depot formulation in managing non-adherent schizophrenic patients, where the benefit of ensured treatment continuity is deemed to outweigh the inherent risks.

8.2 Brand Names and Formulations

Flupentixol is marketed globally under several brand names, which often differ based on the indication (psychosis vs. depression).

• Single-Agent Formulations:
• Depixol®: Primarily marketed for the treatment of schizophrenia and other psychoses.[1]
• Fluanxol®: Primarily marketed for the treatment of depression and anxiety.[1]
• Other names include Psytixol®, Emergil®, and Siplaril®.[8]
• Combination Formulations (with Melitracen):
• Deanxit®: The most common brand name for the combination product.[1]
• Other names include Placida®, Franxit®, Anxidreg®, and Melixol®.[25]

The drug is available in Australia, Canada, and various European countries under the brand names Fluanxol and/or Depixol.[31]

9.0 Conclusion and Expert Insights

Flupentixol is a pharmacologically complex and clinically versatile agent that represents an important tool from the first generation of antipsychotic medications. Its profile is defined by a unique dose-dependent duality: at higher doses, its potent dopamine D2 receptor antagonism provides effective maintenance therapy for non-agitated schizophrenia, while at lower doses, a more nuanced mechanism yields rapid-acting antidepressant and anxiolytic effects.

In contemporary psychiatric practice, the primary and most compelling rationale for the use of Flupentixol lies in its long-acting injectable decanoate formulation. For a specific subset of patients with chronic schizophrenia who struggle with medication adherence, the depot injection offers an invaluable solution, ensuring therapeutic continuity and significantly reducing the risk of relapse. This pharmacokinetic advantage is the main reason for its enduring place in the formularies of many countries, despite the widespread availability of newer agents.

However, this benefit must be rigorously weighed against Flupentixol's substantial safety liabilities, which are characteristic of its class. The high risk of acute extrapyramidal symptoms and the potential for inducing irreversible tardive dyskinesia are significant clinical concerns that are less prevalent with second-generation antipsychotics. The decision to initiate Flupentixol, therefore, requires a meticulous, individualized risk-benefit analysis. Its use should be reserved for clinical scenarios where the problem of non-adherence is paramount and the unique advantages of its depot formulation are judged to outweigh the considerable neurological risks. The divergent regulatory landscape—with widespread approval in Canada, Europe, and Australia but non-approval in the United States—serves as a global testament to this complex clinical calculus, reflecting different national approaches to balancing efficacy, safety, and the availability of therapeutic alternatives. Ultimately, Flupentixol remains a relevant but specialized medication, demanding judicious use and careful patient monitoring by experienced clinicians.

Works cited

1. Flupentixol - Wikipedia, accessed September 27, 2025, https://en.wikipedia.org/wiki/Flupentixol
2. Flupenthixol - MentalHealth.com, accessed September 27, 2025, https://www.mentalhealth.com/library/flupenthixol-uses-dosage-side-effects
3. Flupentixol: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 27, 2025, https://go.drugbank.com/drugs/DB00875
4. Flupentixol tablets - Depixol, Fluanxol. Depression treatment - Patient.info, accessed September 27, 2025, https://patient.info/medicine/flupentixol-tablets-depixol-fluanxol
5. Trans-flupenthixol | C23H25F3N2OS | CID 5281878 - PubChem, accessed September 27, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/trans-Flupentixol
6. flupentixol - Drug Central, accessed September 27, 2025, https://drugcentral.org/drugcard/1211
7. Flupentixol | C23H25F3N2OS | CID 5281881 - PubChem, accessed September 27, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Flupentixol
8. Flupenthixol | CAS#2709-56-0 - MedKoo Biosciences, accessed September 27, 2025, https://www.medkoo.com/products/8023
9. Flupentixol Decanoate - Injection - MyHealth Alberta, accessed September 27, 2025, https://myhealth.alberta.ca/Health/medications/Pages/conditions.aspx?hwid=fdb1210
10. FLUPENTIXOL - ORAL side effects, medical uses, and drug interactions. - MedicineNet, accessed September 27, 2025, https://www.medicinenet.com/flupentixol-oral/article.htm
11. Flupentixol - antipsychotic - Mind, accessed September 27, 2025, https://www.mind.org.uk/information-support/drugs-and-treatments/antipsychotics-a-z/flupentixol/
12. CAS 2709-56-0: Flupentixol - CymitQuimica, accessed September 27, 2025, https://cymitquimica.com/cas/2709-56-0/
13. Flupentixol decanoate | DrugBank Online, accessed September 27, 2025, https://go.drugbank.com/salts/DBSALT000928
14. Fluanxol® Depot 20 mg/mL solution for injection - NEW ZEALAND DATA SHEET, accessed September 27, 2025, https://www.medsafe.govt.nz/profs/datasheet/f/Fluanxolinj.pdf
15. Flupenthixol (PIM 236) - Inchem.org, accessed September 27, 2025, https://www.inchem.org/documents/pims/pharm/flupenth.htm
16. What is the mechanism of Flupentixol Hydrochloride? - Patsnap Synapse, accessed September 27, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-flupentixol-hydrochloride
17. Flupentixol | Davis's Drug Guide - Nursing Central, accessed September 27, 2025, https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/3580014/6/flupentixol
18. Fluanxol® (flupentixol decanoate) - Medsinfo, accessed September 27, 2025, https://rss.medsinfo.com.au/lu/pi.cfm?product=lupfluan
19. Fluanxol Depot - Healthdirect, accessed September 27, 2025, https://www.healthdirect.gov.au/medicines/brand/amt,38591000168101/fluanxol-depot
20. Flupenthixol decanoate - Australian Prescriber - Therapeutic Guidelines, accessed September 27, 2025, https://australianprescriber.tg.org.au/articles/flupenthixol-decanoate.html
21. go.drugbank.com, accessed September 27, 2025, https://go.drugbank.com/drugs/DB00875#:~:text=Flupentixol%20is%20indicated%20for%20maintenance,include%20excitement%2C%20agitation%20or%20hyperactivity.&text=It%20is%20indicated%20for%20the,be%20showing%20signs%20of%20anxiety.
22. Fluanxol 0.5 mg film-coated tablets - Summary of Product Characteristics (SmPC) - (emc), accessed September 27, 2025, https://www.medicines.org.uk/emc/product/998/smpc
23. Antidepressant effects of flupenthixol - PubMed, accessed September 27, 2025, https://pubmed.ncbi.nlm.nih.gov/1771144/
24. Fluanxol® 0.5 mg and 1 mg film-coated tablets flupentixol, accessed September 27, 2025, https://www.medicines.org.uk/emc/files/pil.998.pdf
25. Flupentixol/melitracen, accessed September 27, 2025, http://medbox.iiab.me/kiwix/wikipedia_en_medicine_2019-12/A/Flupentixol/melitracen
26. Melitracen and flupentixol (deanxit) use disorder in Lebanon - PMC, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10195893/
27. Clinical trial: A randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia - ResearchGate, accessed September 27, 2025, https://www.researchgate.net/publication/5519868_Clinical_trial_A_randomized_controlled_cross-over_study_of_flupenthixol_melitracen_in_functional_dyspepsia
28. Flupentixol Completed Phase 2 Trials for Cocaine Related Disorders / Substance-Related Disorders Treatment | DrugBank Online, accessed September 27, 2025, https://go.drugbank.com/drugs/DB00875/clinical_trials?conditions=DBCOND0037604%2CDBCOND0027888&phase=2&purpose=treatment&status=completed
29. (PDF) Off–label long acting injectable antipsychotics in real–world clinical practice: a cross-sectional analysis of prescriptive patterns from the STAR Network DEPOT study - ResearchGate, accessed September 27, 2025, https://www.researchgate.net/publication/361654774_Off-label_long_acting_injectable_antipsychotics_in_real-world_clinical_practice_a_cross-sectional_analysis_of_prescriptive_patterns_from_the_STAR_Network_DEPOT_study
30. PRODUCT MONOGRAPH PrFLUANXOL® FLUANXOL ... - Lundbeck, accessed September 27, 2025, https://www.lundbeck.com/content/dam/lundbeck-com/americas/canada/products/files/fluanxol_product_monograph_english.pdf
31. Fluanxol - NPS MedicineWise, accessed September 27, 2025, https://www.nps.org.au/medicine-finder/fluanxol-depot-injection
32. Flupenthixol Decanoate Injection - Info, Uses & Side Effects | RxHealthMed, accessed September 27, 2025, https://www.rxhealthmed.ca/medication_search/flupenthixol-decanoate-injection/
33. Fluanxol® - Medsafe, accessed September 27, 2025, https://www.medsafe.govt.nz/consumers/cmi/f/fluanxol.pdf
34. Showing BioInteractions for Flupentixol (DB00875) | DrugBank Online, accessed September 27, 2025, https://go.drugbank.com/drugs/DB00875/biointeractions
35. Flupentixol | Davis's Drug Guide - Nursing Central, accessed September 27, 2025, https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/3580014/all/flupentixol?q=administration+drug+food
36. FLUPENTIXOL DECANOATE - Pharmaceutical Benefits Scheme (PBS), accessed September 27, 2025, https://www.pbs.gov.au/medicine/item/2255q-2257t
37. List of nationally authorised medicinal products, accessed September 27, 2025, https://www.ema.europa.eu/en/documents/psusa/flupentixol-list-nationally-authorised-medicinal-products-psusa-00001444-202311_en.pdf
38. Flupentixol (International database) - Drugs.com, accessed September 27, 2025, https://www.drugs.com/international/flupentixol.html